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rest pain, non-healing ischemic ulcers, or both, and if they were not candidates for catheter or surgical revascularization (no expandable/graftable infrapopliteal artery). Fig 1 shows the representative digital subtraction angiography of a "no-option" patient. The diagnosis of Buerger's disease was based on the criteria proposed by Olin: 25 (1) onset before age 45 years; (2) current (recent) history of tobacco use; (3) the presence of distal-extremity ischemia (infrapopliteal or infrabrachial) indicated by claudication, rest pain, ischemic ulcers, or gangrene; (4) exclusion of autoimmune or connective tissue diseases, hypercoagulable states, and diabetes mellitus; (5) exclusion of a proximal source of emboli by echocardiography and arteriography; and (6) consistent arteriographic findings in the clinically involved and non-involved limbs.
We excluded patients who showed allergy to gelatin hydrogel. Other exclusion criteria were: proliferative retinopathy, and evidence of a malignant disorder, which required treatment. We obtained written informed consent from all patients. The Ethics committee of Kyoto University approved the study protocol (protocol # 524). Patient enrollment began in February 2005.
Preparation of bFGF-Incorporated Gelatin Hydrogel Microspheres
Human recombinant bFGF with an isoelectric point of 9.6 was purchased from Kaken Pharmaceutical Co (Tokyo, Japan). A gelatin sample with an isoelectric point of 5.0 was isolated from the bovine bone through the alkaline process (Nitta Gelatin Co, Osaka, Japan). Gelatin hydrogel microspheres were prepared in an aseptic room as previously described. 15, 16 Briefly, gelatin hydrogels were prepared through the glutaraldehyde cross-linking of gelatin in an aqueous solution. The resulting hydrogels were soaked in an aqueous solution of glycine for 3 h to block free aldehyde groups in the hydrogels; they were then washed with double distilled water. Gelatin hydrogels were pulverized by using a homogenizer. The homogenates were passed through sieves with different mesh sizes. The microspheres with a diameter ranging from 50 to 100 m were collected and freeze-dried. After sterilization of the microspheres, we confirmed that there were no residual glutaraldehyde and bacterial contamination in the mircospheres. To incorporate bFGF into gelatin microspheres, an aqueous solution of bFGF (200 g) was applied to freeze-dried microspheres (100 mg); they were then left at an ambient temperature for 1 h. The microspheres slowly released bFGF for approximately 3 weeks.
Study Design
The bFGF-incorporated gelatin hydrogel microspheres were injected into the gastrocnemius of the unilateral ischemic limb (single administration), and its safety and feasibility were evaluated (ie, the phase I-IIa study). We used the dose of bFGF (200 g) in view of safety standards according to our previous animal studies [17] [18] [19] [20] [21] [22] [23] [24] and other clinical reports. 2, 5 We did not have a control group in this study because that was only required in the phase I trial and, more importantly, the patients who participated were ill (ie, they were not candidates for conventional treatments). Oral medications such as vasodilators or antiplatelet drugs remained unchanged during the study period.
No intravenous drugs such as prostaglandins were used during the study period. Patients were followed up to 24 weeks after the treatment.
End-Points
The primary end-point was the safety of the treatment, as evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Ver 3.0. The secondary end-point was feasibility of the treatment, as defined by the improvements in rest pain, the distance walked in 6 min (m), 26, 27 the ankle-brachial pressure index (ABI), transcutaneous oxygen pressure (TcO2, mmHg), laser Doppler perfusion image (LDPI) analyzer 7, [22] [23] [24] (Moor Instruments, Devon, UK) (the mean value of the blood perfusion in the back of the ischemic foot: relative unit), thermography (mean temperature of the ischemic foot: °C), and the status of ulcer-healing. We measured the TcO2 as follows: after cleansing the measurement site with ethanol, we applied the probe, and heated the skin surface to 43.5°C. When a steady-state temperature was achieved, a value expressed in mmHg was recorded. The measurement was performed when patients were breathing room air in a supine position.
The improvements were evaluated by the changes from baseline to week 4 and 24. Rest pain was scaled as previously reported. 7 The blood level of bFGF was measured before treatment, and 1, 2, 7 and 28 days after the treatment.
Procedure
The bFGF-incorporated gelatin hydrogel microspheres were dissolved into 40 ml of saline and intramuscularly injected into each injection site (40 sites), with a 3×3 cm grid and by using a 23-gauge needle under spinal anesthesia. 
Statistical Analysis
All values are expressed as mean ± SD. Changes in variables from baseline to week 4 or week 24 were analyzed with the Wilcoxon t-test. All statistical analyses were performed with Statview software (SAS Institute Inc NC, USA). A p value <0.05 was considered to be significant.
Results
Seven patients were entered into the study (49.3±17. 
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years old, 6 males) ( Table 1 ). Among them, 4 patients (Case 1, 3, 4, and 5) were diagnosed as having Buerger's disease and the other 3 had ASO. Cases 2 and 7 were on chronic hemodialysis. Case 4 had splenomegaly of an unknown origin, and was referred to our institute because he could not have G-CSF for peripheral blood mononuclear cells transplantation for fear of splenic rupture. 28, 29 Primary End-Point There were no deaths or events that were against the NCI CTCAE Ver 3.0 during the whole study period. The treatment did not induce focal inflammation or edema at the injected site. In blood analysis, WBC and CRP transiently elevated, but did not sustain, and normalized within 2 weeks in all patients except 1 patient whose foot ulcer did not heal at 24 weeks (Case 2). Blood levels of bFGF were undetected or within the normal value in all patients. (Tables 1,2; Fig 2) Subjective Parameters The distance walked in 6 min (295±42 m, pretreatment) increased both at 4 weeks (448± 81 m, p=0.023) and 24 weeks (491±85 m, p=0.023). Similarly, the rest pain scale (3.5±0.2, pretreatment) improved both at 4 weeks (1.3±0.42, p=0.015) and 24 weeks (1.0± 0.6, p=0.022). Three patients (Cases 1, 4, and 5) became free from rest pain completely.
Secondary End-Point
Objective Parameters ABI (0.62±0.12, pretreatment) improved at 4 weeks (0.73±0.14, p=0.024), but not at 24 weeks (0.68±0.11). However, at 24 weeks, 4 patients showed an increase in ABI from 9% to 50% from the baseline. TcO2 (53.5±5.2 mmHg) increased both at 4 weeks (66.5±5.0 mmHg, p=0.015) and 24 weeks (65.5±4.0 mmHg, p=0.03). LDPI (436±66 relative unit) also increased both at 4 weeks (520±80 relative unit, p=0.024) and 24 weeks (614±61 relative unit, p=0.015) (Fig 3) .
Five of the 6 patients had a non-healing foot ulcer; the ulcers were completely healed in 3 patients, reduced in 1, and no change in 1. Fig 4 shows the drastic improvement of a non-healed foot ulcer in Case 1. One patient (Case 2) did not show healing of the ulcer progressed stenosis of the superficial femoral artery during the study period.
Discussion
We have shown for the first time that the sustained release of bFGF from gelatin hydrogel microspheres effectively increased blood flow in the ischemic limbs, as assessed by substantial increases in ABI, TcO2, LDPI, and skin temperature. The treatment also significantly improved the distance walked in 6 min and rest pain (complete regression in half of the patients). Ischemic ulcers were completely or partially improved except in 1 case that showed stenosis of the superficial femoral artery during the study period. In addition, the sustained release of bFGF from gelatin hydrogel did not induce focal inflammation at the injected site. Thus, we believe that the method is promising.
The gene transfer of angiogenic growth factors might have shown good results and safety in phase I-IIa clinical trials, although there are still concerns about the unpredictable duration and level of gene expression, or immune or inflammatory responses of genetic materials. [1] [2] [3] [4] [9] [10] [11] In addition, autologous bone marrow cell transplantation needs the aspiration of cells under general anesthesia. [6] [7] [8] Peripheral mononuclear cell transplantation needs the systemic administration of G-CSF; they might induce serious complications such as myocardial infarction, particularly in patients with systemic atherosclesosis, 12, 13 or splenic rupture, although it has been reported to be rare. 28, 29 The sustained release of bFGF from gelatin hydrogel does not require gene therapy, general anesthesia, or G-CSF and therefore might solve these problems.
As a carrier biomaterial, gelatin hydrogel might be suitable for clinical use in terms of easy processability and the versatile controlled release of various growth factors. 15, 16 Gelatin hydrogel is easily processed to microsphere, sheet, or disk. Microspheres are easily dispersed in the water and can be injected into various organs, while sheets could be placed on the heart, bone, and other tissues. [17] [18] [19] [20] [21] [22] [23] [24] Furthermore, by changing the cross-linking extent, each growth factor could be released at a desirable rate and duration for tissue regeneration. 15, 16 They enable a sustained release by a single administration across various fields of regenerative medicine.
We used a sustained release of bFGF because bFGF shows not only potential for angiogenesis and arteriogenesis, but also synergistic effects with other angiogenic agents such as VEGF, 30 HGF, 24, 31 or PDGF-BB. 32 In addition, we have shown that a combination of bFGF and sarpogrelate, a serotonin blocker, 22 or heparin, 23 enhanced collateral vessel flow effectively. Therefore, bFGF might induce more mature vessels and promote more collateral vessel development than other angiogenic agents, which is important to improve long-term results. This advantage is prominent particularly in high-risk patients who have severe diabetes mellitus and hypercholesterolemia, or who are on chronic hemodialysis.
Although this is an initial report of the project of sustained release of bFGF from biodegradable gelatin hydrogel microspheres for patients with severe limb ischemia, the results are promising in its effectiveness to increase blood flow and relieve signs and symptoms. Moreover, the serum level of the bFGF did not increase at any time after the treatment, which suggests no systemic effects of bFGF such as hypotension or proteinuria. 2, 5 If no systemic effects are confirmed, the method will be a purely local treatment that is very safe and suitable for patients with carcinoma or proliferative retinopathy or cerebral/cardiac arterial disease. 9, 10 Cases 5 and 7 showed a high ABI in spite of their severe ischemic symptoms. In Case 5, an ABI measurement of the dorsalis pedis artery was high, however, a pulse of the posterior tibial artery was undetectable. The toe-brachial pressure index might be more reliable than the ABI to the patient. 33 In contrast, a high ABI in Case 7 might be caused by the non-compressible leg arteries with severe atherosclerosis, which is often observed in patients with longstanding diabetes mellitus, in elderly patients, and patients who require hemodialysis for end-staged-renal disease. 27 Therefore, we should have had used toe-brachial pressure index instead of ABI.
There are some limitations in this report/study. First, number of the patients is low becaise this is the first/preliminary report. In addition, the follow-up period was short for the same reason. The fate of the limb circulation late after the treatment should be clarified. Second, because of the phase I (-IIa) nature of the study and because the study deals with "no other option" patients, we did not include a control group who received just a placebo. To confirm the benefit of the method in more detail, a prospective and randomized study will be necessary, perhaps by using patients who are less ill.
In summary, therapeutic angiogenesis by the sustained release of bFGF by using gelatin hydrogel is so far safe and promising. Further investigation is warranted. 
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